Research of Molecular and Metabolic Markers in Oligodendrogliomas Comparatively to Other Brain Tumours
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
At present, diagnosis of oligodendroglioma is made on histological and radiographic criteria in the French Mayo-Ste Anne classification. The less frequent grade A oligodendrogliomas are characterized by no vascular contrast on RMN evaluation comparatively to grade B forms. This benign histological subtype relapses in few cases with a more aggressive histology. To determine these relapsed cases at diagnosis, a collection of tumour begun in February 2004. Then, our study was designed to identify diagnostic molecular and metabolic markers that could eventually be used as a signature characterising grade A versus grade B oligodendrogliomas. The molecular analysis will use genomic techniques like allelotyping study, quantitative real-time PCR, gene sequencing , serial analysis of genomic expression and immunohistochemistry, since the metabolic study will be the spectroscopic examination of in vivo tumour. This study will include paediatric and adult patients followed for oligodendrogliomas, medulloblastomas and gliomas to compare the different tumour signatures. All these results will be correlated to survival and clinical features.
| Condition |
|---|
|
Oligodendrogliomas |
| Study Type: | Observational |
| Study Design: | Observational Model: Case-Only Time Perspective: Prospective |
| Official Title: | Research of Molecular and Metabolic Diagnostic Markers in Oligodendrogliomas A and B Comparatively. |
Eligibility| Ages Eligible for Study: | 1 Year and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Non-Probability Sample |
Patient with oligodendroglioma or medulloblastoma or glioma
Inclusion Criteria:
- Paediatric and adult patients (> 1 year of age)
- Patient with oligodendroglioma or medulloblastoma or glioma
- Possibility of 3 year follow-up
- Patient consent obtained
Exclusion Criteria:
-
Contacts and Locations
More Information
No publications provided
| ClinicalTrials.gov Identifier: | NCT00213876 History of Changes |
| Other Study ID Numbers: | 3154 |
| Study First Received: | September 13, 2005 |
| Last Updated: | August 29, 2011 |
| Health Authority: | France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis) |
Keywords provided by University Hospital, Strasbourg, France:
|
Brain tumours oligodendrogliomas allelotyping SAGE Presence of molecular abnormalities statistically linked to survival or response to chemotherapy |
Additional relevant MeSH terms:
|
Oligodendroglioma Brain Neoplasms Central Nervous System Neoplasms Nervous System Neoplasms Neoplasms by Site Neoplasms Brain Diseases Central Nervous System Diseases |
Nervous System Diseases Glioma Neoplasms, Neuroepithelial Neuroectodermal Tumors Neoplasms, Germ Cell and Embryonal Neoplasms by Histologic Type Neoplasms, Glandular and Epithelial Neoplasms, Nerve Tissue |
ClinicalTrials.gov processed this record on May 22, 2013